Hormonal
Daily subcutaneous liraglutide at 3.0 mg significantly increases weight loss in overweight or obese adults with type 2 diabetes compared to placebo when used as an adjunct to lifestyle interventions.
If you have type 2 diabetes and are overweight, adding daily liraglutide (3.0 mg) to your current diet and exercise plan can lead to significant weight loss (about 6% of body weight over 56 weeks) compared to diet and exercise alone. This medication works by reducing appetite. You should discuss the benefits and potential side effects, such as gastrointestinal issues, with your healthcare provider.
Among overweight and obese participants with type 2 diabetes, use of subcutaneous liraglutide (3.0 mg) daily, compared with placebo, resulted in weight loss over 56 weeks.
Why this rating
Large-scale, randomized, double-blind, placebo-controlled trial with 846 participants across 9 countries.
Source
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
Melanie J. Davies et al. · JAMA · 2015
DOI 10.1001/jama.2015.9676
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →